BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, February 18, 2026
Home
»
Authors
» Jennifer Boggs
Jennifer Boggs
Articles
ARTICLES
MediciNova Prices Japanese IPO, Gets $107M For Pipeline
Feb. 10, 2005
By
Jennifer Boggs
Tercica Gets $48M, Awaits FDA Approval For Growth Factor Drug
Feb. 9, 2005
By
Jennifer Boggs
Tercica Gets $48M, Awaits FDA Approval For Growth Factor Drug
Feb. 9, 2005
By
Jennifer Boggs
Vicuron Reports Positive Phase III Results, Plans Third-Quarter NDA
Feb. 8, 2005
By
Jennifer Boggs
Vicuron Reports Positive Phase III Results, Plans Third-Quarter NDA
Feb. 8, 2005
By
Jennifer Boggs
Enzon Halts Development Plans For Cancer Drug Pegamotecan
Feb. 7, 2005
By
Jennifer Boggs
Enzon Halts Development Plans For Cancer Drug Pegamotecan
Feb. 7, 2005
By
Jennifer Boggs
Myogen's Stock Drops On Delay In Ambrisentan Trial
Feb. 4, 2005
By
Jennifer Boggs
Myogen's Stock Drops On Delay In Ambrisentan Trial
Feb. 4, 2005
By
Jennifer Boggs
Kyorin Pays $21M For ActivX To Be U.S.-Based Research Center
Feb. 3, 2005
By
Jennifer Boggs
View All Articles by Jennifer Boggs
